Filing Details

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

 

(Amendment No. )*

 

Aduro Biotech, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value

(Title of Class of Securities)

 

00739L101

(CUSIP Number)

 

February 21, 2020**

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐       Rule 13d-1(b)

 

☒       Rule 13d-1(c)

 

☐       Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
**	This initial report on Schedule 13G is being filed to reflect holdings which, as a result of an inadvertent administrative error, were not identified as requiring a filing on Schedule 13G at the time such report was due. Upon discovering this oversight, the reporting persons file this Schedule 13G, which reflects information as of June 11, 2020 and information which should have been reported as of February 21, 2020.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 00739L101
1	NAMES OF REPORTING PERSONS
	Vivo Capital IX, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a) ☒
	(b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			933,784 (1)
		6	SHARED VOTING POWER
			0
		7	SOLE DISPOSITIVE POWER
			933,784 (1)
		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	933,784 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	1.2% (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

	(1)	The shares of common stock, $0.0001 par value (the “Common Stock”) of Aduro Biotech, Inc. (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P. as of June 11, 2020. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.
	(2)	Based on 80,837,093 shares of Common Stock of the Issuer outstanding as of April 29, 2020, as reported on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 4, 2020.

 

 

CUSIP No. 00739L101
1	NAMES OF REPORTING PERSONS
	Vivo Opportunity, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (See Instructions)
	(a) ☒
	(b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER
			4,184,776 (1)
		6	SHARED VOTING POWER
			0
		7	SOLE DISPOSITIVE POWER
			4,184,776 (1)
		8	SHARED DISPOSITIVE POWER
			0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	4,184,776 (1)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  (See Instructions)
	☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.2 % (2)
12	TYPE OF REPORTING PERSON  (See Instructions)
	OO

	(1)	The shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. as of June 11, 2020. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.
	(2)	Based on 80,837,093 shares of Common Stock of the Issuer outstanding as of April 29, 2020, as reported on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 4, 2020.

 

 

Item 1.

(a)

Name of Issuer:

 

Aduro Biotech, Inc.

 

(b)

Address of Issuer’s Principal Executive Offices:

 

740 Heinz Avenue

 

Berkeley, California, 94710

 

Item 2.

(a)

Name of Person Filing:

 

This Schedule 13G is filed jointly by Vivo Capital IX, LLC and Vivo Opportunity, LLC. Vivo Capital IX, LLC and Vivo Opportunity, LLC have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

 

(b)

Address of Principal Business Office or, if None, Residence:

 

192 Lytton Avenue, Palo Alto, CA 94301

 

(c)

Citizenship:

 

Vivo Capital IX, LLC is a Delaware limited liability company.

 

Vivo Opportunity, LLC is a Delaware limited liability company.

 

(d)

Title of Class of Securities:

 

Common Stock, $0.0001 par value

 

(e)

CUSIP Number:

 

00739L101

 

Item 3.

If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)

☐

Broker or dealer registered under Section 15 of the Act.

 

(b)

☐

Bank as defined in Section 3(a)(6) of the Act.

 

(c)

☐

Insurance company as defined in Section 3(a)(19) of the Act.

 

(d)

☐

Investment company registered under Section 8 of the Investment Company Act of 1940.

 

(e)

☐

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 

(f)

☐

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 

(g)

☐

A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

 

(h)

☐

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

(i)

☐

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

(j)

☐

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

 

(k)

☐

Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

 

Item 4.

Ownership.

 

(a)

Amount beneficially owned:

 

(1) Vivo Capital IX, LLC

 

The 933,784 shares of Common Stock are held of record by Vivo Capital Fund IX, L.P. as of June 11, 2020. 741,816 shares of Common Stock were held of record by Vivo Capital Fund IX, L.P. as of February 21, 2020. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(2) Vivo Opportunity, LLC

 

The 4,184,776 shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. as of June 11, 2020. 3,324,468 shares of Common Stock were held of record by Vivo Opportunity Fund, L.P. as of February 21, 2020. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

 

(b)

Percent of class:

 

Vivo Capital IX, LLC: 1.2% as of June 11, 2020 (0.9% as of February 21, 2020, based on 80,514,459 shares of Common Stock of the Issuer outstanding as of November 4, 2019, as reported on Form 10-Q for the quarter ended September 30, 2019, filed with the Securities and Exchange Commission on November 7, 2019)

 

Vivo Opportunity, LLC: 5.2% as of June 11, 2020 (4.1% as of February 21, 2020)

 

(c)

Number of shares as to which such person has:

 

(i)

Sole power to vote or to direct the vote:

 

Vivo Capital IX, LLC: 933,784 shares as of June 11, 2020 (741,816 shares as of February 21, 2020)

 

Vivo Opportunity, LLC: 4,184,776 shares as of June 11, 2020 (3,324,468 shares as of February 21, 2020)

 

(ii)

Shared power to vote or to direct the vote: 0

 

(iii)

Sole power to dispose or to direct the disposition of:

 

Vivo Capital IX, LLC: 933,784 shares as of June 11, 2020 (741,816 shares as of February 21, 2020)

 

Vivo Opportunity, LLC: 4,184,776 shares as of June 11, 2020 (3,324,468 shares as of February 21, 2020)

 

(iv)

Shared power to dispose of or to direct the disposition of: 0

 

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

Not Applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.

Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

	Vivo Capital IX, LLC
	June 11, 2020
	(Date)
	/s/ Albert Cha
	(Signature)
	Managing Member
	(Title)
	Vivo Opportunity, LLC
	June 11, 2020
	(Date)
	/s/ Albert Cha
	(Signature)
	Managing Member
	(Title)

 

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value of Aduro Biotech, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing.

 

	Vivo Capital IX, LLC
	June 11, 2020
	(Date)
	/s/ Albert Cha
	(Signature)
	Managing Member
	(Title)
	Vivo Opportunity, LLC
	June 11, 2020
	(Date)
	/s/ Albert Cha
	(Signature)
	Managing Member
	(Title)